Biomedical Research · global
AI-designed lung fibrosis drug shows signals of lower biological age: How should six protein clocks be interpreted?
Blood samples from the rentosertib trial showed younger protein profiles across six models. But this exploratory analysis cannot yet distinguish disease improvement from changes in aging, much less establish human rejuvenation.
Can a drug that treats lung fibrosis also change biological processes associated with aging? Rentosertib, developed by Insilico Medicine, offers a preliminary clue: blood proteins from treated patients showed a decline in predicted age across six “aging clocks.” This opens another window into aging within a disease trial, while leaving a key question: what kind of improvement are the models actually detecting?
The study, published on September 7 in *Nature Biotechnology*, reanalyzed samples from a 12-week phase IIa clinical trial in idiopathic pulmonary fibrosis (IPF). The original trial used a randomized, double-blind, placebo-controlled design; this protein analysis covered 42 participants, tracked 2,841 serum proteins, and applied six independently developed age-prediction models.
These clocks use combinations of proteins to estimate the age characteristics exhibited by the body, with some models also incorporating information associated with mortality risk. All six models detected a trend toward lower predicted biological age in the treatment groups, while the placebo group showed limited changes or a slight increase. However, agreement in the direction of the models does not mean that every dose and time point reached statistical significance.
The most consistent signal appeared at week 4 in the group receiving 30 milligrams twice daily. According to the company’s published interpretation, some models estimated a decline of approximately 3 to 4 years, with one reaching approximately 6 years. This is an age difference calculated from protein data and cannot be interpreted as patients actually becoming several years younger; by week 12, fewer comparisons were statistically significant, and the overall signal appeared closer to a plateau.
The study’s most difficult boundary to cross is that lung disease itself changes blood proteins. The authors explicitly state that these clocks cannot, on their own, distinguish antifibrotic effects from modulation of aging. The dosing group with the clearest improvement in lung function was not the group with the most consistent clock response. Although this offers a clue that the two may be separable, validation in people without IPF is still needed.
Background
Rentosertib is a small-molecule drug candidate targeting the TNIK kinase. According to Insilico, the company used AI to help identify a target associated with fibrosis and aging, then designed molecules through a generative chemistry platform. The new addition here is a protein analysis of an existing clinical trial, extending the scope of evaluation from lung disease to aging indicators, rather than another human trial demonstrating anti-aging efficacy.
The study data have been deposited in a public database under accession number OMIX008341, providing a basis for subsequent scrutiny. However, short-term results from 42 people are insufficient to answer how long the effects might last, whether they can improve everyday functioning, or whether they can extend lifespan. For aging clocks to become tools that support judgments about efficacy, the next step remains establishing a reliable link between their readings and actual health benefits for patients.